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sion within conceptual framework of Andersen’s Behavioral Model was used to 
examine the predisposing, enabling and need characteristics associated with antide-
pressant use. RESULTS: The overall prevalence of antidepressant use was found to 
be 46.22% (95%CI, 45.16–47.27). The most prescribed class of antidepressants was 
SSRIs (67.29%), followed by serotonin modulators (10.05%), SNRIs (6.02%), TCAs 
(5.06%) and MAO inhibitors (0.02%). Citalopram (28%) was the highest prescribed 
individual antidepressant followed by mirtazapine (22.05%). Among the predisposing 
characteristics, age, race, and marital status were signiﬁcantly associated with antide-
pressant drug use. Enabling factors like Medicare or Medicaid payment source and 
facility bed capacity predicted antidepressant use. Among need characteristics, likeli-
hood of receiving antidepressant prescription decreased with increased dependence in 
decision making ability and out of bed mobility. Also presence of depressed mood 
indicators, history of falls and fractures, and an increase in number of medications 
prescribed had positive association with antidepressant prescription. CONCLU-
SIONS: Nearly half of elderly nursing home residents received antidepressants. Pre-
disposing, need, and enabling factors played important roles in use of antidepressants. 
Overall, the study ﬁndings suggest that antidepressant treatment is highly prevalent 
in nursing homes possibly due to increased recognition of symptoms in the elderly 
population.
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OBJECTIVES: Psychotropic use in nursing homes has been a concern due to extensive 
misuse of these agents in the elderly. Very little is known about recent national level 
utilization in nursing homes especially after the introduction of newer psychotropic 
agents. Therefore, this study examined psychotropic drug use patterns among elderly 
nursing home residents at the national level by using the 2004 National Nursing Home 
Survey (NNHS) data. METHODS: This study involved retrospective, cross-sectional 
analysis of the 2004 NNHS. The study sample included patients aged 65 years or 
older. Psychotropic drugs were classiﬁed as antidepressants, sedative/hypnotics, anti-
anxiety, antipsychotics, and stimulants based on existing literature. Psychotropic 
polypharmacy was deﬁned as concomitant use of two or more psychotropic drugs. 
SAS survey procedures were used for descriptive domain analysis and to calculate 95% 
Conﬁdence Intervals (CI) of weighted estimates. RESULTS: According to the 2004 
NNHS, an estimated 0.83 (95% CI, 0.82–0.85) million elderly nursing home residents 
received at least one psychotropic medication for an overall prevalence of 63.18% 
(95% CI, 62.16—64.21), while 25.85% (95% CI: 24.92%–26.77%) received two or 
more psychotropic medications. Antidepressant agents (46.22%, 95% CI: 45.16%–
47.27%) were the most prescribed psychotropic drug class followed by antipsychotics 
agents (24.84%, 95% CI: 23.92%–25.76%). Psychotropic polypharmacy within the 
antidepressant class was highest (5.92%, 95% CI: 5.43%–6.41%) followed by anti-
psychotics (1.17%, 95% CI: 0.94%–1.39%). CONCLUSIONS: Nearly two-third 
elderly nursing home residents received psychotropic medications, while more than 
one in four residents were receiving two or more psychotropic drugs. With increasing 
concerns of inappropriate psychotropic drug use, there is a strong need to monitor 
their usage in this vulnerable population.
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OBJECTIVES: To examine the inﬂuence of inexpensive generic programs on prescrip-
tion medication acquisition behavior of patients. METHODS: Cross-sectional survey 
of 200 consecutive patients during regularly scheduled appointments to an adult 
general medicine clinic. Questions were asked to determine the type of pharmacy 
patients obtained their current prescription medication from; whether they were aware 
of focused programs selling generic medication for a reduced cost; whether they had 
ﬁlled a prescription recently using a reduced cost generic program, and if they did, 
whether they had other medications ﬁlled at the same pharmacy. Demographic data 
was also obtained. Data were analyzed using descriptive statistics. Respondents were 
categorized as having ﬁlled a prescription using an inexpensive generic program or 
not. Differences in demographics and medication-related variables between the two 
groups were analyzed using Student’s t-test for continuous variables or Chi-squared 
test for categorical variables. P value of less than 0.05 were considered statistically 
signiﬁcant. RESULTS: Only 5% of respondents (11 of 210) used an inexpensive 
generic program to ﬁll at least one of their prescriptions. Characteristics of patients 
who tended to use the generic programs included greater number of prescriptions, 
lower household income, no prescription insurance, and be of female gender. The 
study is limited in generalizability due to the small number of respondents in the group 
who had a prescription ﬁlled by an inexpensive generic program. CONCLUSIONS: 
This small study provides encouraging data to support the development of a larger 
study of the inﬂuence of the generic programs on patient behavior in regards to deci-
sion of where to obtain prescriptions. Larger studies may also attempt to determine 
whether these programs improve access to medications that patients may have had 
trouble affording before their inception.
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OBJECTIVES: Duloxetine is approved for the treatment of major depressive disorder 
(MDD) and general anxiety disorder (GAD), and for the management of diabetic 
peripheral neuropathic pain (DPNP) and ﬁbromyalgia. It has also demonstrated sig-
niﬁcant pain relief among patients with chronic lower back pain (CLBP) and osteo-
arthritis. For patients with each of these conditions, this study assessed pain medication 
use prior to duloxetine initiation. METHODS: A large, US administrative claims 
database was used to identify commercially-insured duloxetine initiators during 2007 
and 2008 who had any of the 6 medical conditions mentioned above during the 12 
months prior to duloxetine initiation. Initiation was deﬁned as no duloxetine pill 
coverage in the previous 90 days. Utilization of pain-related medications including 
antidepressants, anticonvulsants, opioids, non-steroidal anti-inﬂammatory drugs 
(NSAIDs), and muscle relaxants, was assessed over the 6 or 12 months prior to 
duloxetine initiation, respectively. RESULTS: The study identiﬁed 44,838 duloxetine 
initiators in 2008, with 13,809, 3,289, 1,501, 8,731, 7,871, and 18,987 in the MDD, 
GAD, DPNP, ﬁbromyalgia, osteoarthritis, and CLBP groups, respectively. Antidepres-
sant use was high across all conditions over the 12 months prior to duloxetine initia-
tion, especially among patients with MDD (83.5%) or GAD (78.8%). Anticonvulsant 
utilization was highest in DPNP (63.4%) and ﬁbromyalgia (55.0%), lowest in GAD 
(39.3%), but similar between other groups (ranged 42.3–48.9%). Opioid use varied 
greatly across groups (55.1–82.8%), with the highest (lowest) use among CLBP (GAD) 
patients. GAD patients had the lowest NSAID use (32.1%), while osteoarthritis 
patients had the highest utilization (59.4%). The use of muscle relaxants ranged 
between 28.2% (GAD and DPNP) and 54.5% (CLBP). Pain medication use in the 
prior 6 months showed similar patterns, but was in general about 10–15 percentage 
points lower. Results for 2007 initiators were similar. CONCLUSIONS: Patients used 
several types of pain medications prior to initiating duloxetine across disease states.
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OBJECTIVES: Over 700 new molecular entities (NMEs) were approved between 1980 
and 2008 in the U.S. Although a small percentage of these products will inevitably be 
discontinued, concerns over safety are purported to be the main impetus for discon-
tinuing a drug from the market. In this study, a trend analysis was performed to 
examine the pattern of discontinued NMEs approved by the FDA from 1980 to 2008. 
METHODS: Data were derived from the FDA, Federal Register, Micromedex, 
Medline, Lexis-Nexis, journal articles, governmental web pages and other publicly 
available documents. A drug was considered discontinued if it was deleted from the 
2009 version of the FDA’s Orange book: Approved Drug Products with Therapeutic 
Equivalence Evaluations. Descriptive statistics, chi-square tests, logistic regression, and 
survival analysis were performed. For the Kaplan-Meier survival curves, drug that 
were not discontinued during the study time-period were censored. RESULTS: A total 
of 703 NMEs were approved during the study period. Of the 101 NMEs that were 
discontinued, 29 were due to safety concerns. Controlling for other factors, the odds 
(OR:2.53; 95% CI:1.42–4.55) of a drug being discontinued for reasons other than 
safety and efﬁcacy were signiﬁcantly higher than the odds of being discontinued for 
safety reasons (p < 0.05). Compared to other therapeutic classes, anti-infective drugs 
were more likely to be discontinued (p < 0.05). Results from the Kaplan-Meier survival 
analysis revealed the estimated probability of discontinuing a NME from the market 
over a 20 year time period was 15.0%. CONCLUSIONS: Survival analysis provided 
useful estimates for the probability of discontinuation. Safety concerns for NMEs were 
not the foremost reasons for drug discontinuation; rather ﬁnancial reasons may con-
tribute to a larger portion of discontinuations. However, additional studies are needed 
to assess how probabilities for drug discontinuation are inﬂuenced by decision-making 
entities regarding drug approval, drug development and innovation, and drug policy.
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OBJECTIVES: With US health care reform proposing to extend Medicare coverage 
to individuals between the ages of 55–64, the pressure for coverage will dramatically 
increase. We examined demand ﬁve drug markets—cholesterol, diabetes, depression, 
hypertension and pain—for this age group compared to others. We also compared the 
cost burden under Medicare Part D compared payers to highlight the demand for 
more affordable drugs from individuals that are not yet eligible for Medicare coverage. 
METHODS: For each drug market, total prescriptions (TRx), new patient prescrip-
tions (NPRx), and average prescription size were obtained for each of the age groups 
analyzed (≤18, 19–35, 36–54, 55–64, ≥65). For each drug market, average out of 
pocket cost (OPC) was also compared between Medicare beneﬁciaries and other 
patients. Data were collected for eight quarters, spanning November 2007 to Novem-
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ber 2009 using SDI’s VONA and VOPA databases. Statistical analyses were performed 
using one-way ANOVA; signiﬁcant results had p < 0.05. RESULTS: Although indi-
viduals ages 55–64 did not dominate the NPRx—ranging from 15% to 26%—this 
group was the second-largest contributor to all prescriptions (TRx) for all the drug 
markets, ranging from 20% to 30%. The average size of prescriptions for this age 
range was statistically equivalent to the average size for the ≥65 population, indicating 
that prescriptions were reﬁlled equally frequently in both populations. Medicare 
beneﬁciaries paid signiﬁcantly less, on average, for drugs in the ﬁve classes compared 
to others by a margin of 20% to 93%. CONCLUSIONS: Individuals approaching 
Medicare eligibility are a demographic with signiﬁcant demand for coverage. They 
show consistently high drug demand; prescription sizes are equal to patients over 65 
and costs signiﬁcantly higher Medicare patients, resulting in a great expenditure for 
covering this population. From the consumer perspective, it is important to recognize 
that the combination of higher OPC and high prescription demand creates a signiﬁcant 
cost burden.
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OBJECTIVES: To assess trends in the utilization and cost of the six protected medica-
tion classes in the Part D program between calendar years 2006 and 2007. METHODS: 
The primary data sources were the prescription drug event data in the Chronic Condi-
tion Warehouse (CCW) matched to the Beneﬁciary Annual Summary for 2006 and 
2007. Data were inﬂation-adjusted for 2007 costs. Results are based on analysis of 
100% data for Medicare beneﬁciaries in the CCW. The six protected medication 
classes under study were anticonvulsants, antidepressants, antineoplastics, antipsy-
chotics, antiretrovirals, and immunosuppressants. RESULTS: Immunosuppressants 
were utilized by the fewest number of beneﬁciaries for 2006 and 2007 (81,974 and 
80,187, respectively); antidepressants were utilized the most (6,040,698 and 
6,645,639, respectively). Immunosuppressants had the lowest aggregate ingredient 
costs for both years ($204 million and $199 million, respectively). Antipsychotics had 
the highest ($4,161 million and 4,807 million, respectively). Ingredient costs to total 
Medicare expenditures ranged from 4.2% for antidepressants to 25.2% for antiretro-
virals in 2006. Results were similar for 2007 (4.5% for antidepressants to 29.4% for 
antiretrovirals). From 2006 to 2007, antidepressants had the lowest increase and 
antiretrovirals the highest. Regarding ingredient cost payment per beneﬁciary, antiret-
rovirals had the highest increase from 2006 to 2007 at 17.6% while immunosuppres-
sants decreased by −0.2%. CONCLUSIONS: Between 2006 and 2007, beneﬁciary 
utilization based on number of users per protected class increased for all classes except 
for immunosuppressants. Aggregate ingredient cost payments increased for all six 
protected classes. Based on ingredient cost payments per beneﬁciary, the immunosup-
pressant class was the only protected class showing a slight decrease; all other classes 
showed an increase.
PHP26
THE IMPACT OF MISUSE OF ANTIBIOTIC THERAPIES ON  
INPATIENT COSTS
Yang L
Peking university, Beijing, Beijing, China
OBJECTIVES: In the 1980s, China launched market-oriented reforms. Public hospi-
tals were encouraged to make their own incomes with the aim of mobilizing medical 
workers and improving hospital efﬁciency. Less government funding resulted in 
deﬁcits for public health institutions, which forced hospitals to generate their own 
revenue by aggressively selling drugs, especially antibiotics. To stem the tide of rising 
public complaints about high medical costs, the NDRC has capped the cost of hun-
dreds of drugs over the years. However, critics argue the price cuts have not been the 
cure since drug manufacturers often change the name and packaging of their drugs to 
escape price controls. Some hospitals and clinics have also turned a blind eye to 
government price caps and refuse to prescribe lower priced alternative drugs. This 
study was designed to evaluate the impact of inappropriate antibiotic use on inpa-
tients’ cost during the hospital stay. METHODS: One thousand cases with antibiotic 
treatment from 10 hospitals of 5 provinces in China in 2005. We created multivariate 
linear regression model for hospital cost and logistic regression model for rationality 
evaluation of antibiotic use. RESULTS: We collected 964 valid cases. Rate of inap-
propriate antibiotic use was 58.4%. Costs of inpatients with inappropriate antibiotic 
use was as 2.75 times as the ones with appropriate use (P < 0.001). Risk factors 
included antibiotic prophylaxis (OR = 2.929), operations (OR = 2.44), long hospital 
stay (OR = 1.021 for every prolonged day) and regional factors. Protection factor was 
in tertiary hospital (OR = 0.510). CONCLUSIONS: Inappropriate antibiotic use 
contributes to inpatients’ high cost. Efforts to control misuse of antibiotic should be 
pursued.
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OBJECTIVES: To study the trends in emergency department (ED) visits due to opioid 
abuse from 1996 to 2007 in United States. METHODS: ED visits attributable to 
opioid abuse were identiﬁed using diagnosis codes (ICD-9-CM codes: 304.0, 304.7, 
305.5 and 965.0) from the National Hospital Ambulatory Medical Care Survey. 
Annual rate of ED visits for opioid abuse per 1000 people was estimated. To increase 
estimation precision, data from two consecutive years were pooled. Bivariate analysis 
and logistic regression were performed to examine the associations of patient demo-
graphic characteristics to ED visits for opioid abuse. Data were analyzed using STATA 
9.2 accounting for complex survey design. RESULTS: Of the total 1,289,529,680 
estimated ED visits made during the 12-year period, 1,633,224 (0.13%) were attribut-
able to opioid abuse. ED visits for opioid abuse increased from 70,748 visits per year 
(0.08%) in 1996–1997 to 208,378 (0.18%) in 2006–2007. The annual rate of ED 
visit for opioid abuse per 1000 people increased from 0.26 in 1996–1997 to 0.70 in 
2006–2007, with an estimated 8% annual increase (p < 0.001). Children and elderly 
were less likely to have an ED visit for opioid abuse compared to nonelderly adults 
aged 34–64(AOR 0.075, 95% CI 0.042–0.134; AOR 0.067, 95% CI 0.026–0.173 
respectively). Females were less likely to have an ED visit for opioid abuse than males 
(AOR 0.555, 95% CI 0.443–0.695).Compared to the West, people in the South and 
Midwest were less likely to have an ED visit for opioid abuse (AOR 0.447, 95% CI 
0.313–0.638; AOR 0.517, 95% CI 0.334–0.799 respectively). Risks of ED visits for 
opioid abuse more than doubled in years 2002–2003 and 2006–2007 (AOR 2.286, 
95% CI 1.420–3.679; AOR 2.329, 95% CI 1.473–3.682 respectively) compared to 
1996–1997. CONCLUSIONS: The number and rate of ED visits for opioid abuse 
increased over time with the highest in 2006–2007.
PHP28
EPISODES OF CARE AND INPATIENT MORTALITY FOLLOWING 
POISONINGS FROM OVER-THE-COUNTER MEDICATIONS IN  
THE UNITED STATES
Hurwitz J, Skrepnek G
University of Arizona College of Pharmacy Center for Health Outcomes and 
PharmacoEconomic Research, Tucson, AZ, USA
OBJECTIVES: To assess and describe episodes of care and inpatient mortality follow-
ing poisonings from over-the-counter (OTC) medications that resulted in hospital 
inpatient admissions in the United States from 2002–2006. METHODS: This retro-
spective study used the nationally-representative sample of hospital discharge records 
from the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost 
Utilization Project (HCUP) Nationwide Inpatient Sample. Cases with any ICD-9 
diagnoses related to poisoning from OTC medications (e.g., codes 965.4, E850.3, 
E945.4) were included for analysis. Descriptive approaches and logistic regression 
were used to assess patient and hospital characteristics, costs, patterns of care and 
utilization, potential disparities of care, and inpatient mortality rates. RESULTS: A 
total of 360,636 inpatient admissions associated with poisonings from OTC medica-
tions occurred from 2002 through 2006. Cases averaged 43.4 ± 20.0 years of age, 3.5 
± 4.6 days length of stay, and $14,808 ± 24,868 in charges. Further, 1.3% of cases 
resulted in patient mortality, which averaged 55.3 ± 19.5 years of age, 5.7 ± 9.1 days 
length of stay, and $44,904 ± 64,738 in charges. The national bill associated with 
OTC poisonings totaled $5.25 billion across the 5 years. Increased odds of inpatient 
mortality were associated (p ≤ 0.05) with patient age, total charges, number of comor-
bidities, patients who self-pay, the regional location of hospitals in the United States, 
and increased case-mix severities. Conversely, decreased odds of inpatient mortality 
were associated (p ≤ 0.05) with shorter lengths of stay, bed-sizes of hospitals, hospitals 
in urban settings, and teaching hospitals. CONCLUSIONS: Inpatient hospitalizations 
associated with poisonings from OTC medications accounts for a substantial burden 
of illness often exceeding 50,000 cases per year and summing to $5.25 billion over 
ﬁve years. Despite a small percentage of inpatient mortality, further research is needed 
on the costs and outcomes following discharge, as well as those treated and released 
solely in emergency departments, and OTC poisonings among children.
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OBJECTIVES: To examines the presence of spatial clusters across states in total 
number of prescription drugs ﬁlled at retail pharmacies in US METHODS: Using data 
on total number of prescription drugs ﬁlled at retail pharmacies by each state in US 
from Vector One and National by Verispan, L.L.C in 2008, Moran’s I statistic for 
global spatial dependence (i.e. cluster) was used to identify if clusters existed. In 
Moran’s I, weight matrix to deﬁne neighbors was utilized using Rook 1st order contigu-
ity weight, Queen 1st order contiguity and 4-nearest neighbors. Permutations using 
999 repetitions was used to calculate p-values in each weight matrix. RESULTS: 
Signiﬁcant positive global spatial autocorrelation in total number of prescription drugs 
ﬁlled at retail pharmacies was found regardless of any weight matrix. Moran’s I using 
Rook weight was 0.259 and p-value was 0.003. Moran’s I using Queen weight and 
4-nearest neighbors were 0.263 (p-value = 0.002) and 0.412 (p-value = 0.001), respec-
tively. CONCLUSIONS: Findings showed that clusters or non-randomness in total 
number of prescription drugs ﬁlled at retail pharmacies existed. Non-randomness 
implies two things. In statistical analysis, this cluster effect should be considered. And, 
policy makers should consider clusters when they make a decision for health care 
distributions.
